Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-15), TriSalus Life Sciences's 3-1 Month Momentum % is -14.32%.
The industry rank for TriSalus Life Sciences's 3-1 Month Momentum % or its related term are showing as below:
TLSI's 3-1 Month Momentum % is ranked worse than 65.8% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: -7.915
vs TLSI: -14.32
TriSalus Life Sciences (NAS:TLSI) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
TriSalus Life Sciences 3-1 Month Momentum % Related Terms
TLSI vs TMCI, LAB, SENS: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's 3-1 Month Momentum % falls into.
TriSalus Life Sciences (NAS:TLSI) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a 3-1 Month Momentum % of -14.32% as of Jul. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on TriSalus Life Sciences and its competitors. According to the industry distribution chart, TriSalus Life Sciences ranks #558 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is TriSalus Life Sciences' 3-1 Month Momentum % too high?
TriSalus Life Sciences' current 3-1 Month Momentum % is -14.32%. Based on the distribution chart, TriSalus Life Sciences ranks #558 out of 848 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' 3-1 Month Momentum % compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #558 out of 848 companies for 3-1 Month Momentum %. This places TriSalus Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on TriSalus Life Sciences and its competitors. TriSalus Life Sciences's current 3-1 Month Momentum % is -14.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Fairly Valued. The stock's GF Value™ is $4.30, compared to a current price of $4.05 — trading 5.8% below its estimated fair value. The current 3-1 Month Momentum % is -14.32%. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current 3-1 Month Momentum % is -14.32% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $4.05 is trading 5.8% below its estimated GF Value™ of $4.30.
GuruFocus considers TriSalus Life Sciences to be Fairly Valued.
Key valuation signals for TLSI:
3-1 Month Momentum %: -14.32%
GF Value™: $4.30 vs. price of $4.05 (5.8% below fair value)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
